ABUS vs IONS · P/E 5.4, rev $6.2M vs rev $226.6M
Arbutus Biopharma Corp (ABUS) versus Ionis Pharmaceuticals Inc (IONS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Ionis Pharmaceuticals Inc (IONS) is a biotechnology company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported IONS revenue for 2024-12-31 was $226.6M. Net income was -$104.3M. Revenue was down 30.2% from 2023-12-31 to 2024-12-31. IONS currently screens at market cap $12.28B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. IONS currently screens at market cap $12.28B.
Not investment advice. Open the ABUS and IONS stock pages for the full models.
Not investment advice.